Plasma-based tumor genetics for monitoring disease progression: what can we learn from a tube of blood?

Por Mack, Philip C.
Publicado no J Thorac Oncol (2015)

Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies

Por Chinn, Danielle C., Holland, William S., Mack, Philip C.
Publicado no J Cancer Res Clin Oncol (2014)

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

Por Li, Tianhong, Kung, Hsing-Jien, Mack, Philip C., Gandara, David R.
Publicado em 2013

Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines

Por Holland, William S., Chinn, Danielle C., Lara, Primo N., Gandara, David R., Mack, Philip C.
Publicado no J Cancer Res Clin Oncol (2014)

Multidrug Resistant Protein-Three Gene Regulation by the Transcription Factor Nrf2 in Human Bronchial Epithelial and Non-Small Cell Lung Carcinoma

Por Mahaffey, Christopher M., Zhang, Hongqiao, Rinna, Alessandra, Holland, William, Mack, Philip C., Forman, Henry Jay
Publicado em 2009

Aberrant Regulation of the MRP3 Gene in Non-Small Cell Lung Carcinoma

Por Mahaffey, Christopher M., Mahaffey, Nichole C., Holland, William, Zhang, Hongqiao, Gandara, David R., Mack, Philip C., Forman, Henry Jay
Publicado em 2012

Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy

Por Holland, William S., Tepper, Clifford G., Pietri, Jose E., Chinn, Danielle C., Gandara, David R., Mack, Philip C., Lara, Primo N.
Publicado no Cancer Chemother Pharmacol (2011)

Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (NCI # 7097)

Por Ramalingam, Suresh S., Belani, Chandra P., Mack, Philip C., Vokes, Everett E., Longmate, Jeffrey, Govindan, Ramaswamy, Koczywas, Marianna, Ivy, S. Percy, Gandara, David R.
Publicado em 2010

Algorithm for Codevelopment of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Intrapatient Tumor Heterogeneity

Por Gandara, David R., Li, Tianhong, Lara, Primo N., Mack, Philip C., Kelly, Karen, Miyamoto, Suzanne, Goodwin, Neal, Beckett, Laurel, Redman, Mary W.
Publicado em 2012

SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)

Por Ignatius Ou, Sai-Hong, Moon, James, Garland, Linda L., Mack, Philip C., Testa, Joseph R., Tsao, Anne S., Wozniak, Antoniette J., Gandara, David R.
Publicado no J Thorac Oncol (2015)

Disease control rate at 8 weeks predicts subsequent survival in platinum-treated extensive stage small cell lung cancer: Results from the Southwest Oncology Group (SWOG) database

Por Lara, Primo N., Moon, James, Redman, Mary W., Semrad, Thomas J., Kelly, Karen, Allen, Jeffrey, Gitlitz, Barbara, Mack, Philip C., Gandara, David R.
Publicado no Clin Lung Cancer (2015)

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

Por Li, Tianhong, Christensen, Scott D., Frankel, Paul H., Margolin, Kim A., Agarwala, Sanjiv S., Luu, Thehang, Mack, Philip C., Lara, Primo N., Gandara, David R.
Publicado em 2010

A PHASE II STUDY OF GEMCITABINE AND CAPECITABINE IN PATIENTS WITH ADVANCED RENAL CELL CANCER (RCC): SOUTHWEST ONCOLOGY GROUP STUDY S0312

Por Van Veldhuizen, Peter J., Hussey, Michael, Lara, Primo N., Mack, Philip C., Gandour-Edwards, Regina, Clark, Joseph I., Lange, Marianne K., Crawford, E. David
Publicado em 2009

Relevance of platinum sensitivity status in relapsed/refractory extensive stage small cell lung cancer (ES-SCLC) in the modern era: A patient level analysis of SWOG trials

Por Lara, Primo N., Moon, James, Redman, Mary W., Semrad, Thomas J., Kelly, Karen, Allen, Jeffrey W., Gitlitz, Barbara J., Mack, Philip C., Gandara, David R.
Publicado no J Thorac Oncol (2015)

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer

Por Ho, Cheryl, Davies, Angela M., Sangha, Randeep S., Lau, Derick, Lara, Primo, Chew, Helen K., Beckett, Laurel, Mack, Philip C., Riess, Jonathan W., Gandara, David R.
Publicado no Invest New Drugs (2013)

Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy

Por Semrad, Thomas J., Kim, Edward J., Tanaka, Michael S., Sands, Jacob, Roberts, Chris, Burich, Rebekah A., Li, Yu, Gandara, David R., Lara, Primo, Mack, Philip C.
Publicado no Cancer Treat Res Commun (2017)

Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial

Por Sangha, Randeep, Davies, Angela M., Lara, Primo N., Mack, Philip C., Beckett, Laurel A., Hesketh, Paul J., Lau, Derick, Li, Tianhong, Perkins, Natasha, Gandara, David R.
Publicado em 2011

Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer

Por Allen, Jeffrey W., Moon, James, Redman, Mary, Gadgeel, Shirish M., Kelly, Karen, Mack, Philip C., Saba, Hanna M., Mohamed, Mohamed K., Jahanzeb, Mohammad, Gandara, David R.
Publicado em 2014

SWOG 0709: Randomized Phase II Trial of Erlotinib vs. Erlotinib plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as...

Por Lara, Primo N., Moon, James, Hesketh, Paul J., Redman, Mary W., Williamson, Stephen K., Akerley, Wallace L., Hirsch, Fred R., Mack, Philip C., Gandara, David R.
Publicado no J Thorac Oncol (2015)

A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Patients with Inoperable Locally Advanced Stag...

Por Wozniak, Antoinette J., Moon, James, Thomas, Charles R., Kelly, Karen, Mack, Philip C., Gaspar, Laurie E., Raben, David, Fitzgerald, Thomas J., Pandya, Kishan J., Gandara, David R.
Publicado no Clin Lung Cancer (2015)